Media
Recent News
01/01/2019
Amgen Announces Webcast of 2018 Fourth Quarter and Full Year Financial Results Teach For America and the Amgen Foundation Renew

FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Teach For America and the

01/01/2019
Teach For America and the Amgen Foundation Renew Partnership to Improve Math and Science Education in Urban and Rural Renew

FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Teach For America and the

01/01/2019
Browse by Year :
January 2019
01/01/2019
FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Teach For America and the Amgen Foundation Renew
Source: Times of India
01/05/2019
FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Teach For America and the Amgen Foundation Renew
Source: Times of India
01/15/2019
FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Teach For America and the Amgen Foundation Renew
Source: Times of India
01/15/2019
FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Teach For America and the Amgen Foundation Renew
Source: Times of India
Febraury 2019
01/02/2019
FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Teach For America and the Amgen Foundation Renew
Source: Times of India
01/02/2019
FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Teach For America and the Amgen Foundation Renew
Source: Times of India
01/02/2019
FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Teach For America and the Amgen Foundation Renew
Source: Times of India
01/15/2019
FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors Teach For America and the Amgen Foundation Renew
Source: Times of India
© 2019 Avesthagen Limited